Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo purchased 291 shares of the firm’s stock in a transaction on Monday, September 24th. The stock was bought at an average price of GBX 913 ($11.89) per share, for a total transaction of £2,656.83 ($3,460.77).

Lorenzo Tallarigo also recently made the following trade(s):

  • On Wednesday, August 22nd, Lorenzo Tallarigo purchased 302 shares of Oxford BioMedica stock. The stock was bought at an average price of GBX 881 ($11.48) per share, for a total transaction of £2,660.62 ($3,465.70).
  • On Monday, July 23rd, Lorenzo Tallarigo purchased 306 shares of Oxford BioMedica stock. The stock was bought at an average price of GBX 867 ($11.29) per share, for a total transaction of £2,653.02 ($3,455.80).

Shares of Oxford BioMedica stock opened at GBX 918.30 ($11.96) on Tuesday. Oxford BioMedica plc has a twelve month low of GBX 4.44 ($0.06) and a twelve month high of GBX 13.19 ($0.17).

OXB has been the topic of several research analyst reports. Peel Hunt restated a “buy” rating on shares of Oxford BioMedica in a research report on Thursday, May 31st. Jefferies Financial Group lowered shares of Oxford BioMedica to a “hold” rating in a research report on Wednesday, June 13th.

Oxford BioMedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Featured Story: Asset Allocation and Your Retirement

Insider Buying and Selling by Quarter for Oxford BioMedica (LON:OXB)

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.